Rein Therapeutics Inc. (RNTX) Stock Price & Analysis
Rein Therapeutics Inc. (RNTX) closed at USD 0.63 on Thursday, October 15, 2026, up 7.17% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 0.59; the Oct 15, 2026 session ranged USD 0.55–0.66 on volume of 1,372,904 shares. Market capitalization is $54.18M, with a 52-week range of USD 0.54–2.18 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RNTX.md
Key facts (RNTX)
- Analysts: Buy (mean 1.50 on a 1–5 scale) (2 analysts), mean target USD 6 (range 4–8).
- Total return with dividends: 1Y -50.9% vs S&P 500 +18.1%; 5Y -96.9% vs S&P 500 +85.1%.
Analysts (RNTX)
Consensus Buy (mean 1.50 on a 1–5 scale), 2 analysts; mean target USD 6 (low 4, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-18 | HC Wainwright & Co. | Reiterated | Buy | $8 |
| 2026-07-20 | Maxim Group | Initiated | Buy | $4 |
Total return (dividends reinvested) (RNTX)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -50.9% | -96.9% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -51.1% | -50.0% |
| Volatility (annualized) | 89.5% | 94.8% |
| Max drawdown | -68.8% (Apr 2026→Oct 2026) | -96.9% (Oct 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 0.63 |
|---|---|
| Change | ▲ 7.17% (up) |
| Previous Close | USD 0.59 |
| Open | USD 0.6 |
| Day Range | USD 0.55 – 0.66 |
| 52-Week Range | USD 0.54 – 2.18 |
| Volume | 1,372,904 shares |
| Market Cap | $54.18M |
| Exchange | NCM |
Technical Analysis (RNTX)
Nexqual's technical model rates RNTX "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.78 (neutral) |
| vs SMA50 | Below (USD 0.78) |
| MACD | -0.03 (negative) |
Analyst Ratings (RNTX)
Wall Street analysts rate RNTX "Buy" based on 2 analysts, with a mean price target of USD 6 (range USD 4–8), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 6 |
| High Target | USD 8 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (RNTX)
| Revenue Estimate | $0 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.1 vs est -0.17 ▲ beat |
| 2026-03-31 | USD -0.19 vs est -0.49 ▲ beat |
| 2025-12-31 | USD -1.22 vs est -0.22 ▼ miss |
| 2025-09-30 | USD -0.21 vs est -0.24 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (RNTX)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -96.42% |
| Current Ratio | 4.27 |
| Total Cash | $40.65M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (RNTX)
Nexqual rates Rein Therapeutics Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $41M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$19M (TTM) |
| Efficiency | Critical — ROE -96%, ROA -21.0% |
Ownership (RNTX)
| Insider Ownership | +5.02% |
|---|---|
| Institutional Ownership | +52.39% |
| Shares Outstanding | 86.27M |
| Float | 66.11M |
| Short % of Float | +0.76% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (RNTX)
Rein Therapeutics Inc. is led by James Brian Windsor (age 59), CEO, President & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO, President & Director | James Brian Windsor (age 59) |
|---|---|
| Interim CFO & Principal Accounting Officer | Timothy M. Cunningham (age 63) |
| Chief Scientific Officer | Cory M. Hogaboam |
Major Backers & Investors (RNTX)
Notable institutional backers of Rein Therapeutics Inc. include Voss Capital, LP, Cable Car Capital, LP, Adar1 Capital Management, LLC , according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Voss Capital, LP | 6.1% |
| Cable Car Capital, LP | 6.02% |
| Adar1 Capital Management, LLC | 5.22% |
| Bios Capital Management, LP | 3.46% |
| Ikarian Capital, LLC | 3.42% |
| Great Point Partners LLC | 2.98% |
| Citadel | 2.83% |
| Velan Capital Investment Management LP | 1.97% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 7.83% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt